Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SAGE Stock Forecast 2026-2027
$8.68
Current Price
$544.94M
Market Cap
Buy 0
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to SAGE Price Targets
+38.2%
To High Target of $12.00
-2.1%
To Median Target of $8.50
-30.9%
To Low Target of $6.00
SAGE Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-4.7%
1 Year Change
0.0%
Year-to-Date Change
-24.1%
From 52W High of $11.44
+87.9%
From 52W Low of $4.62
📊 TOP ANALYST CALLS
Did SAGE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sage Therapeutics is one of their latest high-conviction picks.
Latest SAGE Stock Price Targets & Analyst Predictions
Based on our analysis of 29 Wall Street analysts, SAGE has a neutral consensus with a median price target of $8.50 (ranging from $6.00 to $12.00). The overall analyst rating is Buy (6.0/10). Currently trading at $8.68, the median forecast implies a -2.1% downside. This outlook is supported by 0 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Douglas Tsao at HC Wainwright & Co., projecting a 38.2% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 30.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SAGE Analyst Ratings
0
Buy
7
Hold
0
Sell
SAGE Price Target Range
Low
$6.00
Average
$8.50
High
$12.00
Current: $8.68
Latest SAGE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SAGE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2025 | Scotiabank | George Farmer | Sector Perform | Downgrade | $9.20 |
| Jun 20, 2025 | Baird | Joel Beatty | Neutral | Maintains | $9.00 |
| Jun 17, 2025 | Canaccord Genuity | Sumant Kulkarni | Hold | Maintains | $8.50 |
| Jun 17, 2025 | Truist Securities | Joon Lee | Hold | Maintains | $9.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $12.00 |
| Jun 17, 2025 | Piper Sandler | David Amsellem | Neutral | Downgrade | $8.50 |
| Jun 16, 2025 | Needham | Ami Fadia | Hold | Reiterates | $N/A |
| Apr 30, 2025 | Needham | Ami Fadia | Hold | Reiterates | $N/A |
| Apr 25, 2025 | Needham | Ami Fadia | Hold | Reiterates | $N/A |
| Feb 12, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $12.00 |
| Feb 12, 2025 | Canaccord Genuity | Sumant Kulkarni | Hold | Maintains | $8.00 |
| Feb 12, 2025 | Wedbush | Laura Chico | Neutral | Reiterates | $6.00 |
| Feb 12, 2025 | Scotiabank | George Farmer | Sector Outperform | Maintains | $12.00 |
| Feb 12, 2025 | Needham | Ami Fadia | Hold | Reiterates | $N/A |
| Jan 2, 2025 | Piper Sandler | David Amsellem | Overweight | Maintains | $9.00 |
| Dec 16, 2024 | Stifel | Paul Matteis | Hold | Maintains | $6.00 |
| Nov 21, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Upgrade | $4.00 |
| Nov 21, 2024 | TD Cowen | Ritu Baral | Hold | Maintains | $9.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $14.00 |
| Nov 20, 2024 | Needham | Ami Fadia | Hold | Reiterates | $N/A |
Sage Therapeutics Inc. (SAGE) Competitors
The following stocks are similar to Sage Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SAGE
Sage Therapeutics
mkt cap
544.94M
Sage Therapeutics Inc. (SAGE) Financial Data
Sage Therapeutics Inc. has a market capitalization of $544.94M with a P/E ratio of -1.3x. The company generates $70.41M in trailing twelve-month revenue with a 77.1% profit margin.
Revenue growth is +265.8% quarter-over-quarter, while maintaining an operating margin of -171.2% and return on equity of -60.4%.
Valuation Metrics
Market Cap
$544.94M
Enterprise Value
$190.82M
P/E Ratio
-1.3x
PEG Ratio
0.0x
Price/Sales
7.7x
Growth & Margins
Revenue Growth (YoY)
+265.8%
Gross Margin
+100.2%
Operating Margin
-171.2%
Net Margin
+77.1%
EPS Growth
+265.8%
Financial Health
Cash/Price Ratio
+67.1%
Current Ratio
9.2x
Debt/Equity
3.1x
ROE
-60.4%
ROA
-33.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sage Therapeutics Inc. (SAGE) Business Model
About Sage Therapeutics Inc.
What They Do
Develops novel medicines for brain disorders.
Business Model
Sage Therapeutics generates revenue by developing and commercializing innovative treatments for psychiatric and neurological disorders, focusing on significant unmet medical needs such as major depressive disorder and postpartum depression. The company invests in research to create compounds that target critical brain receptors, aiming to bring new therapies to market.
Additional Information
Based in Cambridge, Massachusetts, Sage Therapeutics is positioned in the healthcare and biotechnology sectors, contributing to advancements in the pharmaceutical industry. The company's innovative research and development efforts are crucial for addressing challenges in treating central nervous system disorders, impacting millions globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
353
CEO
Mr. Barry E. Greene
Country
United States
IPO Year
2014
Website
www.sagerx.comSage Therapeutics Inc. (SAGE) Latest News & Analysis
Latest News
Quick Summary
Sage Potash Corp. (TSXV: SAGE) is initiating site preparation for its 2026 drilling program at the Sage Plain Potash Project in Utah, including access road and site leveling activities.
Why It Matters
Sage Potash's drilling program signals progress in its flagship project, potentially enhancing resource estimation and market confidence, which may positively impact stock performance and investor interest.
Source: Newsfile Corp
Market Sentiment:
Neutral
Sage Potash Secures All Permits for its Drilling Program at Sage Plain Potash Project in Utah
1 month ago
Quick Summary
Sage Potash Corp. has received all necessary approvals and permits for drilling at its Sage Plain project in Utah, following a site inspection on May 28, 2026.
Why It Matters
Sage Potash Corp. has secured all necessary permits for its drilling project in Utah, signaling progress that may enhance production potential and boost investor confidence in future revenues.
Source: Newsfile Corp
Market Sentiment:
Neutral
Sage (SAGE) Q2 Revenue Jumps 264%
11 months ago
Quick Summary
Sage (SAGE) reported a 264% increase in revenue for Q2.
Why It Matters
A 264% revenue increase indicates strong growth potential for Sage, potentially boosting shareholder value and attracting investor interest.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Sage Therapeutics reported increased revenue for Q2 2025, driven by investment and growth in ZURZUVAE, aimed at improving care for postpartum depression.
Why It Matters
Sage Therapeutics' revenue growth and commitment to advancing postpartum depression treatment could indicate strong market potential and future profitability, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Sage Therapeutics reported a quarterly loss of $0.79 per share, better than the expected loss of $0.96, and improved from a loss of $1.7 per share a year prior.
Why It Matters
Sage Therapeutics' smaller-than-expected loss improves outlook, indicating potential operational efficiency and investor confidence, which could positively impact stock performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Sage Therapeutics is set to be acquired by Supernus Pharmaceuticals for $8.50 per share in cash, plus a contingent value right potentially worth up to $3.50 per share.
Why It Matters
The investigation into Sage Therapeutics' sale could impact share prices and investor sentiment, as legal scrutiny may affect the deal's completion and future valuations.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SAGE Stock
What is Sage Therapeutics Inc.'s (SAGE) stock forecast for 2027?
Based on our analysis of 29 Wall Street analysts, Sage Therapeutics Inc. (SAGE) has a median price target of $8.50. The highest price target is $12.00 and the lowest is $6.00.
Is SAGE stock a good investment in 2027?
According to current analyst ratings, SAGE has 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.68. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SAGE stock?
Wall Street analysts predict SAGE stock could reach $8.50 in the next 12 months. This represents a -2.1% decrease from the current price of $8.68. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sage Therapeutics Inc.'s business model?
Sage Therapeutics generates revenue by developing and commercializing innovative treatments for psychiatric and neurological disorders, focusing on significant unmet medical needs such as major depressive disorder and postpartum depression. The company invests in research to create compounds that target critical brain receptors, aiming to bring new therapies to market.
What is the highest forecasted price for SAGE Sage Therapeutics Inc.?
The highest price target for SAGE is $12.00 from Douglas Tsao at HC Wainwright & Co., which represents a 38.2% increase from the current price of $8.68.
What is the lowest forecasted price for SAGE Sage Therapeutics Inc.?
The lowest price target for SAGE is $6.00 from Laura Chico at Wedbush, which represents a -30.9% decrease from the current price of $8.68.
What is the overall SAGE consensus from analysts for Sage Therapeutics Inc.?
The overall analyst consensus for SAGE is neutral. Out of 29 Wall Street analysts, 0 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are SAGE stock price projections?
Stock price projections, including those for Sage Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:12 PM UTC